Partnerships allow us to leverage complementary skills, technologies and areas of expertise. Through these relationships, we accelerate and enhance how we discover, develop and deliver our therapies to patients. In many instances we have collaborated on multiple projects with partners, often over many years — as we work to sustain collaborations that are successful and mutually beneficial.    

Under our agreement with Adimab, we have licensed its proprietary discovery platform, allowing us to accelerate our efforts in finding the next generation of antibodies to treat neurodegenerative and autoimmune diseases.

Biogen and AGTC announced a broad collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases. The collaboration focuses on the development of a portfolio of AGTC’s therapeutic programs, including both a clinical stage candidate and a preclinical candidate for orphan diseases of the retina that can lead to blindness in children and adults. The agreement also includes options for early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition.

Biogen joined the CTTV in a pioneering public-private collaboration to improve the success rate for discovering new medicines. CTTV fosters deep, ongoing interactions between academic and industry members for the purpose of developing open, transformative approaches to selecting and validating novel targets in drug development. Biogen’s membership followed the launch of the new CTTV Target Validation Platform, which helps researchers identify therapeutic targets for new medicines.

Biogen’s collaboration with Eisai on therapeutics for Alzheimer’s disease (AD) has strengthened the pipelines of both companies. Through our agreement, Biogen and Eisai will codevelop and cocommercialize two of Eisai’s product candidates for AD, while Eisai has the option to codevelop and cocommercialize two of Biogen’s AD product candidates. Eisai’s therapeutics have the potential to reduce the Aß plaques that form in the brains of patients, as well as to slow the formation of new plaques, potentially improving symptoms and suppressing disease progression.

Biogen’s collaboration with BioFocus, a subsidiary of Galapagos NV, advances our efforts to discover therapies for immunological diseases. This collaboration specifically focuses on identifying and validating novel targets in scleroderma, an autoimmune disease that causes hardening of the skin and can also impact organs.

In 2013, we announced our fourth collaboration with Ionis Pharmaceuticals. This most recent initiative combines Biogen’s expertise in neurology with Ionis’ leadership in antisense technology. The goal is to leverage antisense technology in advancing the treatment of neurological diseases, including myotonic dystrophy type 1 (the most common form of muscular dystrophy in adults) and spinal muscular atrophy (SMA) in children.

Since 2012 Samsung Biologics and Biogen have collaborated through Samsung Bioepis Co., Ltd., a joint venture to develop, manufacture and market biosimilars. The strategic collaboration between the two companies has enabled Samsung Bioepis to build the capabilities needed to develop high-quality biosimilars. At the end of 2013, Biogen announced that it had entered into an agreement with Samsung Bioepis to commercialize anti-TNF biosimilar product candidates in Europe, including biosimilars for widely used therapies to treat conditions such as rheumatoid arthritis, psoriasis and Crohn’s disease.